Gapping up
In reaction to earnings/guidance:
- VSCO +7% (reaffirms guidance; $250 accelerated share repurchase program)
Other news:
- NRXP +12.2% (files Breakthrough Therapy Designation request for ZYESAMI)
- LHDX +9.4% (announces a new distribution agreement for at least 600000 tests in 2022 with Co-Defend and Co-Protect)
- CALX +6.8% (to join S&P MidCap 400)
- ENS +2.9% (announces integration of its ABSL Lithium-ion batteries into the NASA Webb Telescope launch)
- QDEL +1.2% (Antigen Tests Detect the Omicron Variant)
- LQDA +1.1% (announces stipulation of partial judgment in favor of Liquidia filed in Hatch-Waxman litigation)
- DAR +0.9% (to acquire Valley Proteins for $1.1 bln in cash)
Analyst comments:
- ORTX +6.7% (resumed with an Overweight at Cantor Fitzgerald)
- NRIX +2.7% (initiated with a Buy at H.C. Wainwright)
- VXRT +2.2% (resumed with a Buy at Jefferies)
- PEAR +1.7% (initiated with a Buy at Citigroup)
- VAXX +1.5% (resumed with a Buy at Jefferies)
- BTX +1.3% (initiated with an Overweight at Cantor Fitzgerald)
- AKAM +0.8% ( initiated with a Buy at DA Davidson)